Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PARIS AND CAMBRIDGE, MASS., MAY 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING PHYSICS-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED FDA ACCEPTANCE OF A PROTOCOL AMENDMENT TO THE ONGOING PIVOTAL NANORAY-312 STUDY.

NANOBIOTIX ANNOUNCES PROTOCOL AMENDMENT TO ONGOING GLOBAL PHASE 3 HEAD AND NECK CANCER STUDY

PRECLINICAL EVALUATION IN MICE ASSESSED THE POTENTIAL OF THE NANOBIOTIX NANOPRIMER TO OVERCOME COMMON BARRIERS FACED BY LIPID NANOPARTICLE(LNP)-DELIVERED THERAPIES RELATED TO RAPID LIVER CLEARANCE PRE-TREATMENT WITH NANOPRIMER FOLLOWED BY ADMINISTRATION OF LNP-DELIVERED RECOMBINANT DNA (LNP-DNA) DESIGNED FOR ANTI-TUMOR IMMUNOTHERAPY SHOWED INCREASED SYSTEMIC BIOAVAILABILITY, REDUCED HEPATIC TOXICITY, AND REDUCED CGAS-STING RELATED INFLAMMATION COMPARED TO LNP-DNA ADMINISTERED WITHOUT THE NANOPRIMER DATA PRESENTED AT THE 2026 ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PARIS AND CAMBRIDGE, MASS., APRIL 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: NBTX - THE COMPANY), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED THE PRESENTATION OF NEW PRECLINICAL DATA EVALUATING ITS NANOPRIMER PLATFORM IN SEQUENCE WITH LIPID NANOPARTICLE-DELIVERED RECOMBINANT DNA (LNP-DNA) AT THE 2026 ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR).

NANOBIOTIX ANNOUNCES NEW PRECLINICAL DATA SUPPORTING IMPROVED SYSTEMIC BIOAVAILABILITY AND REDUCED TOXICITY FOR LNP-DELIVERED DNA IMMUNOTHERAPY AFTER PRE-TREATMENT WITH NANOPRIMER TECHNOLOGY

IN ACCORDANCE WITH ARTICLES L.233-8 II OF THE FRENCH COMMERCIAL CODE AND 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY (AUTORIT DES MARCHS FINANCIERS) IN ACCORDANCE WITH ARTICLES L.233-8 II OF THE FRENCH COMMERCIAL CODE AND 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY (AUTORIT DES MARCHS FINANCIERS)

VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY

GLOBAL DEVELOPMENT PROGRAM FOR JNJ-1900 (NBTXR3) PROCEEDED AS PLANNED, BUILDING TOWARD OPPORTUNITY TO ADDRESS ONE OF THE LARGEST UNTAPPED MARKETS IN ONCOLOGY THROUGH LEAD PROGRAMS IN HEAD AND NECK CANCER AND LUNG CANCER CLINICAL RESULTS REPORTED ACROSS MULTIPLE TUMOR TYPES INCLUDING ESOPHAGEAL CANCER, PANCREATIC CANCER, MELANOMA, HEAD AND NECK CANCER, AND LUNG CANCER THAT SUPPORTED THE BROAD POTENTIAL OF JNJ-1900 (NBTXR3) ACROSS SOLID TUMORS TREATED WITH RADIOTHERAPY NEXT TO THE COMPLETION OF THE TRANSFER OF SPONSORSHIP FOR NANORAY-312 STRENGTHENED FINANCIAL POSITION THROUGH THE CLOSING OF A NON-DILUTIVE ROYALTY FINANCING WITH HEALTHCARE ROYALTY FOR UP TO $71 MILLION AND AN AMENDMENT TO THE GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) ADVANCED THE CURADIGM NANOPRIMER PLATFORM WITH FOUR NEW PATENT APPLICATIONS FILED, NEW IN VIVO DATA PRESENTATIONS, EXTERNAL COLLABORATION MOMENTUM BUILDING, AND THE LAUNCH OF CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) ACTIVITIES TO SUPPORT BOTH INTERNAL PIPELINE AND EXTERNAL COLLABORATIONS CASH RUNWAY EXTENDED INTO EARLY 2028 WITH 52.8 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2025 CLINICAL DATA READOUTS EXPECTED IN 2026 FROM PHASE 1 AND 2 STUDIES IN NSCLC (RE-IRRADIATION), PANCREATIC CANCER, MELANOMA AND ESOPHAGEAL CANCER CONFERENCE CALL AND WEBCAST SCHEDULED FOR APRIL 1, 2026, AT 8:00 A.M. EDT / 2:00 P.M.

NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS FULL YEAR 2025 FINANCIAL RESULTS

CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, APRIL 1ST, 2026, AT 8:00 AM EDT / 2:00 PM CEST CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, APRIL 1ST, 2026, AT 8:00 AM EDT / 2:00 PM CEST

NANOBIOTIX TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2025 OPERATIONAL AND FINANCIAL UPDATE ON MARCH 31ST, 2026

PARIS AND CAMBRIDGE, MASS., MARCH 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: NBTX - THE COMPANY), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ISSUED THE FOLLOWING STATEMENT IN RESPONSE TO RECENT MEDIA SPECULATION CONCERNING INTENTIONS FOR A POTENTIAL PUBLIC TAKE-OVER.

NANOBIOTIX STATEMENT REGARDING RECENT MEDIA SPECULATION

IN ACCORDANCE WITH ARTICLES L.233-8 II OF THE FRENCH COMMERCIAL CODE AND 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY (AUTORIT DES MARCHS FINANCIERS)

PARIS AND CAMBRIDGE, MASS., FEB. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: NBTX - THE COMPANY), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THESE UPCOMING CONFERENCES IN MARCH:

Nanobiotix S.A.

NBTX

Price

Financial Reports

No items found.

Press Releases

Nanobiotix S.A.

NBTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NBTX